A · Agilent Technologies, Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-11-23 21:30 UTC | Q4 2026 Agilent Technologies Inc. Earnings Conference Call | Earnings call |
Recent news
| Date | Headline |
|---|---|
| 2026-11-04 | Agilent Completes Acquisition of Proscia |
| 2026-11-02 | Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows |
| 2026-10-29 | Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23 |
| 2026-10-27 | Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research |
| 2026-10-13 | Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence |
| 2026-10-01 | Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows |
| 2026-09-29 | Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers |
| 2026-09-21 | Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control |
| 2026-09-16 | CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share |
| 2026-09-16 | Agilent Announces Cash Dividend of 25.5 Cents per Share |
| 2026-09-10 | Agilent to Participate in J.P. Morgan U.S. All Stars Conference |
| 2026-09-08 | Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors |
| 2026-09-04 | Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System |
| 2026-09-01 | Agilent Introduces the Cary 635 FTIR Spectrometer |
| 2026-08-26 |
Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
Delivers strong Q3 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Third-quarter fiscal year 2026 Revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core (1) compared with the third quarter of fiscal year 2025. GAAP operating margin of 23.6%, expanded by 290 basis points year-over-year and 190 basis points sequentially. Non-GAAP operating margin (2) of 28.3% (including an approximately 110 basis point net benefit from tariff refunds), expanded by 320 basis points year-over-year and 190 basis points sequentially. GAAP net income of $362 million; earnings per share (EPS) of $1.28, an increase of 8% from the third quarter of fiscal year 2025. Non-GAAP net income (3) of $459 million (including a $17 million net benefit from tariff refunds); non-GAAP EPS (3) of $1.62 (including a $0.06 net benefit from tariff refunds), an increase of 18% from the third |
| 2026-07-29 |
Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
Eastern Institute of Technology professor recognized for advancing PFAS and emerging contaminant analysis Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health research. Professor Cai is a globally recognized leader in environmental and bioanalytical chemistry. His research focuses on advancing analytical methods to detect trace environmental contaminants, including PFAS, endocrine-disrupting chemicals, and persistent organic pollutants. By combining high-sensitivity analytical techniques with organoid-based toxicological models, his work aims to improve understanding of how environmental |
| 2026-07-28 |
Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is |
| 2026-07-23 | Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
| 2026-07-14 | Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma |
| 2026-07-08 | Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis |
| 2026-07-01 | Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight |
| 2026-06-25 | Agilent Completes Acquisition of Biocare Medical |
| 2026-06-03 | Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation |
| 2026-06-02 | Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma |
| 2026-05-28 | Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory |
Past events
Source: https://www.investor.agilent.com/news-and-events/events/default.aspx